Warrants of series TO3 were subscribed to approximately 90.4 percent and Pharmacolog receives approximately SEK 2.3 million

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ACTION OTHER THAN THAT REQUIRED BY SWEDISH LAW.

Pharmacolog i Uppsala AB (publ) (”Pharmacolog” or the ”Company”) announces today the outcome of the exercise of warrants of series TO3, which  were issued in connection with the Compan’'s rights issue of units on Nasdaq First North Growth Market which was completed in July 2023. In total, 42,269,834 warrants of series TO3 were exercised, corresponding to approximately 90.4 percent of the total number of outstanding warrants of series TO3, for subscription of 42,269,834 series B shares. Pharmacolog will receive approximately SEK 2.3 million before issue costs through the exercise of the warrants of series TO3.

Background

The exercise period for the warrants of series TO3 took place from February 9, 2024 up to and including February 23, 2024. The subscription price per share for exercising the warrants of series TO3 was set to SEK 0.054.

In total, 42,269,834 warrants of series TO3 were exercised for subscription of 42,269,834 series B shares, meaning that approximately 90.4 percent of all outstanding warrants of series TO3 were exercised for subscription of series B shares.

Exercised warrants have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted to shares within approximately three (3) weeks.

Number of shares, share capital and dilution

Through the exercise of the warrants of series TO3, the number of shares in Pharmacolog increases by 42,269,834 series B shares, from 66,250,342 to 108,520,176. The share capital will increase by SEK 422,698.34, from SEK 662,503.42 to SEK 1,085,201.76.

For existing shareholders who did not exercise any warrants of series TO3, the dilution amounts to approximately 39.0 percent based on the number of shares following exercise of the warrants of series TO3.

Advisors

Mangold Fondkommission AB is the financial advisor to Pharmacolog in connection with the exercise of the warrants. Eversheds Sutherland Advokatbyrå AB is the legal advisor to the Company in connection with the exercise of the warrants.

This disclosure contains information that Pharmacolog is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 27-02-2024 11:38 CET.